Carfilzomib (PR-171)

Product information

$103.95

Description

Description

Carfilzomib is a derivative of the microbially-derived natural product epoxomycin. It irreversibly inhibits the chymotrypsin-like activity of the 20S proteasome with high potency and selectivity at several orders of magnitude over epoxomycin. In 2012, Carfilzomib was approved by the FDA for use in patients with relapsed and refractory multiple myeloma. It is in clinical trials for other cancers as well

Overview

Overview

Powder; no buffer, Souce: chemical synthesis, Buffer: Powder; no buffer

Additional details

Downloads

Downloads

http://www.ubpbio.com/temp/F1300%20F1301_Carfilzomib%20(PR-171)_Datasheet.pdf

SKU

UBP-F1300

Manufacturer Part Number

F1300

UOM

5 mg